๐๐ง๐ญ๐ข๐๐๐๐ญ๐๐ซ๐ข๐๐ฅ ๐ฆ๐๐๐ข๐๐ข๐ง๐๐ฌ ๐๐๐ง ๐ฌ๐๐ฏ๐ ๐ฅ๐ข๐ฏ๐๐ฌ. ๐๐ฎ๐ญ ๐๐จ ๐ฐ๐ ๐ค๐ง๐จ๐ฐ ๐ก๐จ๐ฐ ๐ญ๐ก๐๐ฒ ๐๐ซ๐ ๐๐ฎ๐ง๐๐๐ – ๐๐ง๐ ๐ฐ๐ก๐๐ญ ๐ง๐๐๐๐ฌ ๐ญ๐จ ๐๐ก๐๐ง๐ ๐ ๐ญ๐จ ๐๐๐ญ๐ญ๐๐ซ ๐ฌ๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ ๐ญ๐ก๐๐ข๐ซ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ?
Weโre very happy to share that our new paper โ๐๐ฏ ๐ฐ๐ท๐ฆ๐ณ๐ท๐ช๐ฆ๐ธ ๐ฐ๐ง ๐จ๐ญ๐ฐ๐ฃ๐ข๐ญ ๐ฑ๐ถ๐ฃ๐ญ๐ช๐ค ๐ข๐ฏ๐ฅ ๐ฑ๐ฉ๐ช๐ญ๐ข๐ฏ๐ต๐ฉ๐ณ๐ฐ๐ฑ๐ช๐ค ๐ช๐ฏ๐ท๐ฆ๐ด๐ต๐ฎ๐ฆ๐ฏ๐ต๐ด ๐ช๐ฏ๐ต๐ฐ ๐ข๐ฏ๐ต๐ช๐ฃ๐ข๐ค๐ต๐ฆ๐ณ๐ช๐ข๐ญ ๐ต๐ฉ๐ฆ๐ณ๐ข๐ฑ๐ฆ๐ถ๐ต๐ช๐ค๐ด (2017โ23)โ, has just been published in the ๐๐๐ง๐๐๐ญ ๐๐ข๐๐ซ๐จ๐๐!
๐๐ก๐๐ญ ๐๐ข๐ ๐ฐ๐ ๐๐ข๐ง๐?
ยทย ย ย ย ย ย Investment peaked in 2020 and has since fallen by 18%
ยทย ย ย ย ย $2.51 billion was invested by 130 funders, with funding highly concentrated among a few major players
ยทย ย ย ย ย ย Early-research funding has declined, while clinical development remains relatively stable
ยทย ย ย ย ย ย Funding broadly aligns with WHO priority pathogens, though some gaps remain
ยทย ย ย ย ย ย Traditional approaches dominate, while many non-traditional strategies, like phages, peptides etc., struggle to translate
๐๐ก๐ฒ ๐ญ๐ก๐ข๐ฌ ๐ฆ๐๐ญ๐ญ๐๐ซ๐ฌ
As private investment continues to shrink, antibacterial innovation increasingly relies on public funding, philanthropy, and partnerships
Initiatives such as Global Antibiotic R&D Partnership (GARDP) and CARB-X are essential – but they alone cannot sustain the system
๐๐ฎ๐ซ ๐ญ๐๐ค๐-๐ก๐จ๐ฆ๐ ๐ฆ๐๐ฌ๐ฌ๐๐ ๐
Sustained investment is necessary, but stronger strategic alignment across funders, sectors, and R&D stages is essential to deliver new antibacterial medicines that meet priority public health needs
This work is the result of a close collaboration between Global Antibiotic R&D Partnership (GARDP) and the Global AMR R&D Hub.
